Cargando…
Clinical Scenarios for Discordant Anti-Xa
Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880685/ https://www.ncbi.nlm.nih.gov/pubmed/27293440 http://dx.doi.org/10.1155/2016/4054806 |
_version_ | 1782433831323697152 |
---|---|
author | Vera-Aguilera, Jesus Yousef, Hindi Beltran-Melgarejo, Diego Teng, Teng Hugh Jan, Ramos Mok, Mary Vera-Aguilera, Carlos Moreno-Aguilera, Eduardo |
author_facet | Vera-Aguilera, Jesus Yousef, Hindi Beltran-Melgarejo, Diego Teng, Teng Hugh Jan, Ramos Mok, Mary Vera-Aguilera, Carlos Moreno-Aguilera, Eduardo |
author_sort | Vera-Aguilera, Jesus |
collection | PubMed |
description | Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review. Guidelines and current literature search: we used PubMed, Medline, Embase, and MEDION, from 2000 to October 2013. Results. Anti-Xa test is widely used; however the assay underestimates heparin concentration in the presence of significant AT deficiency, pregnancy, end stage renal disease, and postthrombolysis and in patients with hyperbilirubinemia; limited published data evaluating the safety and effectiveness of anti-Xa assays for managing UH therapy is available. Conclusions and Relevance. To our knowledge this is the first paper that summarizes the most common causes in which this assay can be affected, several “day to day” clinical scenarios can modify the outcomes, and we concur that these rarely recognized scenarios can be affected by negative outcomes in the daily practice. |
format | Online Article Text |
id | pubmed-4880685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48806852016-06-12 Clinical Scenarios for Discordant Anti-Xa Vera-Aguilera, Jesus Yousef, Hindi Beltran-Melgarejo, Diego Teng, Teng Hugh Jan, Ramos Mok, Mary Vera-Aguilera, Carlos Moreno-Aguilera, Eduardo Adv Hematol Review Article Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review. Guidelines and current literature search: we used PubMed, Medline, Embase, and MEDION, from 2000 to October 2013. Results. Anti-Xa test is widely used; however the assay underestimates heparin concentration in the presence of significant AT deficiency, pregnancy, end stage renal disease, and postthrombolysis and in patients with hyperbilirubinemia; limited published data evaluating the safety and effectiveness of anti-Xa assays for managing UH therapy is available. Conclusions and Relevance. To our knowledge this is the first paper that summarizes the most common causes in which this assay can be affected, several “day to day” clinical scenarios can modify the outcomes, and we concur that these rarely recognized scenarios can be affected by negative outcomes in the daily practice. Hindawi Publishing Corporation 2016 2016-05-12 /pmc/articles/PMC4880685/ /pubmed/27293440 http://dx.doi.org/10.1155/2016/4054806 Text en Copyright © 2016 Jesus Vera-Aguilera et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Vera-Aguilera, Jesus Yousef, Hindi Beltran-Melgarejo, Diego Teng, Teng Hugh Jan, Ramos Mok, Mary Vera-Aguilera, Carlos Moreno-Aguilera, Eduardo Clinical Scenarios for Discordant Anti-Xa |
title | Clinical Scenarios for Discordant Anti-Xa |
title_full | Clinical Scenarios for Discordant Anti-Xa |
title_fullStr | Clinical Scenarios for Discordant Anti-Xa |
title_full_unstemmed | Clinical Scenarios for Discordant Anti-Xa |
title_short | Clinical Scenarios for Discordant Anti-Xa |
title_sort | clinical scenarios for discordant anti-xa |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880685/ https://www.ncbi.nlm.nih.gov/pubmed/27293440 http://dx.doi.org/10.1155/2016/4054806 |
work_keys_str_mv | AT veraaguilerajesus clinicalscenariosfordiscordantantixa AT yousefhindi clinicalscenariosfordiscordantantixa AT beltranmelgarejodiego clinicalscenariosfordiscordantantixa AT tengtenghugh clinicalscenariosfordiscordantantixa AT janramos clinicalscenariosfordiscordantantixa AT mokmary clinicalscenariosfordiscordantantixa AT veraaguileracarlos clinicalscenariosfordiscordantantixa AT morenoaguileraeduardo clinicalscenariosfordiscordantantixa |